FrancophonIA/ELRC3.0 huggingface dataset:
English: Advanced Accelerator Applications, 47014 Meldola (FC), Italy Advanced Accelerator Applications, Technopole de l'Aube,10430 Rosières près Troyes, France Seibersdorf Labor GmbH, 2444 Seibersdorf, Austria Instituto Tecnológico PET, SA, 28040 Madrid, Spain Advanced Accelerator Applications, 50100 La Almunia de Doña Godina, Zaragoza, Spain Advanced Accelerator Applications, 10010 Colleretto Giacosa (TO) Italy Nucleis SA, 4000 Liège, Belgium
Croatian: Advanced Accelerator Applications, 47014 Meldola (FC), Italija Advanced Accelerator Applications, Technopole de l'Aube,10430 Rosières près Troyes, Francuska Seibersdorf Labor GmbH, 2444 Seibersdorf, Austrija Instituto Tecnológico PET, SA, 28040 Madrid, Španjolska Advanced Accelerator Applications, 50100 La Almunia de Doña Godina, Zaragoza, Španjolska Advanced Accelerator Applications, 10010 Colleretto Giacosa (TO) Italija Nucleis SA, 4000 Liège, Belgija
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER GE Healthcare AS
Croatian: 11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET GE Healthcare AS
English: IV
Croatian: V
English: Osteogenic cells Ovaries
Croatian: Osteogene stanice
English: Resuming breast-feeding should be in agreement with the nuclear medicine doctor who will supervise the procedure.
Croatian: Nastavak dojenja morate dogovoriti s liječnikom specijalistom nuklearne medicine koji će nadgledati postupak.
English: Renal/hepatic impairment The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Croatian: Oštećenje funkcije bubrega/jetre Farmakokinetika kod bolesnika s oštećenjem funkcije bubrega ili jetre nije okarakterizirana.
English: How VIZAMYL is stored
Croatian: Kako se primjenjuje VIZAMYL
English: Ethanol, anhydrous
Croatian: Etanol, bezvodni
English: Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials.
Croatian: Čuvanje radiofarmaceutika mora biti u skladu s nacionalnom regulativom o radioaktivnim tvarima.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION VIZAMYL 400 MBq/mL solution for injection flutemetamol (18F)
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA VIZAMYL 400 MBq/ml otopina za injekciju flutemetamol (18F) i.v.
English: For precautions with respect to environmental hazard see section 6.6.
Croatian: Za mjere opreza vezano uz onečišćenje okoliša vidjeti dio 6.6.
English: The patient's head should be tilted so that the anterior commissure-posterior commissure (ACPC) plane is at right angles to the bore-axis of the PET scanner with the head positioned in a suitable head support.
Croatian: Postavite odgovarajući podložak ispod bolesnikove glave i podignite mu bradu tako da prednja i stražnja komisurna linija (ACPC) budu pod pravim kutovima u odnosu na os PET snimača.
English: Reducing head movement with tape or other flexible head restraints may be employed.
Croatian: Možete dodatno pričvrstiti bolesnikovu glavu pomoću trake ili drugog fleksibilnog stabilizatora kako biste ograničili pomicanja glave.
English: Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.
Croatian: Čuvanje radiofarmaceutika bit će u skladu s nacionalnim propisima o radioaktivnim tvarima.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL LABEL / 15 mL
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA NA BOČICI / 15 ml
English: If at any time in the preparation of this product the integrity of the vial is compromised, it should not be used.
Croatian: Ako se za vrijeme pripreme lijeka bočica ošteti, lijek se ne smije koristiti.
English: GE Healthcare d.o.o.
Croatian: GE Healthcare B.V.
English: This may need to be taken into consideration by patients on a controlled sodium diet.
Croatian: Tu je činjenicu potrebno uzeti u obzir u bolesnika na prehrabi s kontroliranim unosom natrija.
English: SPECIAL STORAGE CONDITIONS Storage in accordance with national regulation on radiopharmaceuticals.
Croatian: Skladištiti u skladu s nacionalnim propisima o radiofarmaceuticima.
English: Advanced Accelerator Applications, 47014 Meldola (FC), Italy Advanced Accelerator Applications, Technopole de l'Aube,10430 Rosières près Troyes, France Seibersdorf Labor GmbH, 2444 Seibersdorf, Austria Instituto Tecnológico PET, SA, 28040 Madrid, Spain Advanced Accelerator Applications, 50100 La Almunia de Doña Godina, Zaragoza, Spain Advanced Accelerator Applications, 10010 Colleretto Giacosa (TO) Italy Nucleis SA, Allée du Six-Août, 8, 4000 Liège, Belgium MAP Medical Technologies, Saukonpaadenranta 2, 00180 Helsinki, Finland ITEL Telecomunicazioni, Via Labriola (ZI, Lotto 40), 70037, Ruvo di Puglia, Italy Helmholtz-Zentrum Dresden-Rossendorf e.V., Zentrum für Radiopharmazeutische Tumorforschung, Bautzner Landstraβe 400, 01328 Dresden, Germany
Croatian: Advanced Accelerator Applications, 47014 Meldola (FC), Italija Advanced Accelerator Applications, Technopole de l'Aube,10430 Rosières près Troyes, Francuska Seibersdorf Labor GmbH, 2444 Seibersdorf, Austrija Instituto Tecnológico PET, SA, 28040 Madrid, Španjolska Advanced Accelerator Applications, 50100 La Almunia de Doña Godina, Zaragoza, Španjolska Advanced Accelerator Applications, 10010 Colleretto Giacosa (TO) Italija Nucleis SA, Allée du Six-Août, 8, 4000 Liège, Belgija MAP Medical Technologies, Saukonpaadenranta 2, 00180 Helsinki, Finska ITEL Telecomunicazioni, Via Labriola (ZI, Lotto 40), 70037, Ruvo di Puglia, Italija Helmholtz-Zentrum Dresden-Rossendorf e.V., Zentrum für Radiopharmazeutische Tumorforschung, Bautzner Landstraβe 400, 01328 Dresden, Njemačka
English: Iterative or filtered back projection reconstruction is recommended with a slice thickness of 2 to 4 mm, and an axial matrix size of 128 x 128 with pixel sizes of approximately 2 mm. Where a postsmoothing filter may be applied with a full width half maximum (FWHM) of not more than 5 mm, the filter FWHM should be chosen to optimize the signal-to-noise ratio while preserving the sharpness of the reconstructed image.
Croatian: Pri rekonstrukciji iterativne projekcije ili unatražne projekcije filtriranih podataka preporučuje se debljina slojeva od 2 do 4 mm i veličina aksijalne matrice od 128 x 128 s veličinom piksela od otprilike 2 mm.
English: There is no evidence of flutemetamol (18F) binding to soluble forms of
Croatian: Nema dokaza o vezivanju flutemetamola (18F) za topljive oblike amiloida.
English: A recent co-registered Computed Tomography (CT) scan or Magnetic Resonance (MR) scan of the patient to obtain a fused PET-CT or PET-MR image is recommended in cases of uncertainty about the location of grey matter and of the grey/white matter border in the PET scan (see section 4.4 Interpretation of VIZAMYL images).
Croatian: U slučaju nejasnoća u lokalizaciji sive tvari i granice između sive i bijele tvari na PET snimci preporuča se fuzionirati snimku s nedavno učinjenom kompjuteriziranom tomografijom (CT) ili magnetskom rezonancom (MR) kako bi se dobile PET-CT ili PET-MR snimke (vidjeti dio 4.4 Interpretacija snimaka dobivenih pomoću VIZAMYL-a).
English: Talk to your nuclear medicine doctor before you are given VIZAMYL if you: have kidney problems have liver problems are pregnant or think you may be pregnant are breast-feeding
Croatian: imate problema s bubrezima imate problema s jetrom ste trudni ili mislite da biste mogli biti trudni dojite
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL LABEL / 10 mL
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA NA BOČICI / 10 ml
English: Each mL of solution contains flutemetamol (18F) 400 MBq at reference date and time.
Croatian: Svaki ml otopine sadrži 400 MBq flutemetamola (18F) na referentni datum i vrijeme.
English: Lower large intestine wall Lungs
Croatian: Stijenka donjeg dijela debelog crijeva Pluća
English: Tell your doctor straight away if you notice any of the signs above.
Croatian: Ako primijetite bilo koji od gore navedenih simptoma, odmah obavijestite svog liječnika.
English: GE International Inc. Tel: +371 780 7086
Croatian: Tel: +371 780 7086
English: No carcinogenicity and reproductive toxicology studies have been performed with flutemetamol (18F).
Croatian: S flutemetamolom (18F) nisu provođene studije kancerogenosti i reproduktivne toksičnosti.
English: You should avoid any close contact with young children for 24 hours following the injection.
Croatian: Trebate izbjegavati bilo kakav bliski kontakt s malom djecom tijekom prvih 24 sata nakon injekcije.
English: VIZAMYL is for multidose use.
Croatian: VIZAMYL je namijenjen za višekratnu primjenu.
English: Upper large intestine Bladder
Croatian: Gornji dio debelog crijeva Mjehur
English: Facial hypoaesthesia Pruritus
Croatian: Hipoestezija lica Pruritus
English: Chest discomfort Feeling hot Asthenia Fatigue
Croatian: Nelagoda u prsištu Osjećaj vrućine Astenija
English: If you get any side effects, talk to your nuclear medicine doctor.
Croatian: Ako imate bilo kakvih pitanja, kontaktirajte svog liječnika specijalista nuklearne medicine.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING SHIELD LABEL / 10 mL
Croatian: NALJEPNICA NA ZAŠTITNOM PAKIRANJU / 10 ml
English: Close contact with infants should be restricted during the initial 24 hours following injection.
Croatian: Potrebno je izbjegavati bliski kontakt s djecom tijekom prvih 24 sata nakon injekcije.
English: can detect β-amyloid diffuse plaques when they are frequent.
Croatian: In vivo, flutemetamol (18F) može detektirati β-amiloidne difuzne plakove kada su učestali.
English: VIZAMYL is supplied in 10-mL and 15-mL Type I glass vials with halobutyl rubber stoppers and aluminium seals.
Croatian: VIZAMYL se isporučuje u bočicama od 10 ml i 15 ml od stakla tipa
English: Multidose vial
Croatian: Veličina pakiranja
English: A positive scan indicates a moderate to frequent density.
Croatian: Pozitivan rezultat snimanja znači srednju do visoku gustoću.
English: A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. For the limitations in the interpretation of a positive scan, see sections 4.4 and 5.1.
Croatian: Negativan rezultat snimanja karakteriziran je rijetkim plakovima ili nepostojanjem plakova, što nije u skladu s dijagnozom AB.
English: Skin tightness Swelling face
Croatian: Zatezanje kože Oticanje lica
English: Anaphylactoid reaction
Croatian: Krvožilni poremećaji
English: Dyspnoea Hyperventilation Throat irritation
Croatian: Dispneja Hiperventilacija
English: Sodium dihydrogen phosphate dihydrate Disodium hydrogen phosphate dodecahydrate Water for injections
Croatian: Natrijev hidrogenfosfat dodekahidrat
English: Advanced Accelerator Applications S.r.l.
Croatian: Advanced Accelerator Applications S.r.l. Via Ribes 5
English: GE Healthcare Inc. Tel.: +370 68 723 753
Croatian: Tel.: +370 68 723 753
English: Pallor
Croatian: Gušterača
English: Tel: + 385 1 6170 280
Croatian: GE Healthcare d.o.o. Tel: + 385 1 6170 280
English: Close contact with infants and pregnant women should be restricted during the initial 24 hours following the injection.
Croatian: Nakon postupka Potrebno je izbjegavati bliski kontakt s djecom i trudnicama tijekom prvih 24 sata nakon injekcije.
English: Muscle tightness Musculoskeletal pain
Croatian: Nadbubrežne žlijezde Mozak
English: Contact your nuclear medicine doctor if you have any questions.
Croatian: Razgovarajte sa svojim liječnikom specijalistom nuklearne medicine prije nego primite VIZAMYL ako:
English: Interpretation of VIZAMYL images
Croatian: Primjena VIZAMYL-a i provedba postupka
English: Gastrointestinal disorders
Croatian: Mučnina Povraćanje Dispepsija
English: If you are breast-feeding
Croatian: Žučni mjehur
English: The recommended dose is 300 micrograms per kilogram body weight once every 3 weeks.
Croatian: Preporučena doza iznosi 300 mikrograma po kilogramu tjelesne težine jednom svaka 3 tjedna.
English: Further information on Onpattro can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Onpattro možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Onpattro?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Onpattro?
English: The most common side effects with Onpattro (which may affect more than 1 in 10 people) are peripheral oedema (swelling, especially of the ankles and feet) and infusion-related reactions including pain, nausea (feeling sick), headache, tiredness, dizziness, cough and breathing problems, reddening of the skin, rapid heartbeat, low or high blood pressure and swelling of the face.
Croatian: Najčešće nuspojave povezane s lijekom Onpattro (mogu se javiti u više od 1 na 10 osoba) jesu periferni edem (oticanje, osobito gležnjeva i stopala) i reakcije povezane s infuzijom, uključujući bol, mučninu, glavobolju, umor, vrtoglavicu, kašalj i probleme s disanjem, crvenilo kože, brz rad srca, nizak ili visok krvni tlak i oticanje lica.
English: What is Onpattro and what is it used for?
Croatian: Što je Onpattro i za što se koristi?
English: The medicine is available as a solution for infusion (drip) into a vein.
Croatian: Lijek je dostupan kao otopina za infuziju (drip) u venu.
English: What are the risks associated with Onpattro?
Croatian: Koji su rizici povezani s lijekom Onpattro?
English: Onpattro may be given at home by a healthcare professional if the patient has had at least 3 infusions given in hospital without problems.
Croatian: Zdravstveni radnik može dati lijek Onpattro kod kuće ako je bolesnik primio barem 3 infuzije u bolnici bez problema.
English: Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Croatian: Više informacija o statusu lijeka za rijetke bolesti možete naći ovdje: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Side effects reported with Onpattro are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Onpattro pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Why is Onpattro authorised in the EU?
Croatian: Zašto je lijek Onpattro odobren u EU-u?
English: Regarding safety, the most serious side effects are infusion-related reactions and these can be managed with premedication and changes to infusion speed.
Croatian: Kad je riječ o sigurnosti, najteže su nuspojave reakcije povezane s infuzijom, kojima se može upravljati premedikacijom i promjenama u brzini infuzije.
English: As for all medicines, data on the use of Onpattro are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Onpattro kontinuirano se prate.
English: For more information about using Onpattro, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Onpattro pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
English: Onpattro is used in adult patients in the first two stages of the nerve damage (stage 1, when the patient is able to walk unaided, and stage 2, when the patient can still walk but needs help).
Croatian: Onpattro se primjenjuje u odraslih bolesnika u prvim dvama stadijima oštećenja živaca (1. stadij, kada bolesnik može hodati bez pomoći i 2. stadij, kada bolesnik može hodati, ali mu je potrebna pomoć).
English: Onpattro contains the active substance patisiran.
Croatian: Onpattro sadrži djelatnu tvar patisiran.
English: The broken protein forms amyloid deposits in tissues and organs around the body, including around nerves, where it interferes with their normal functions.
Croatian: Raspadnuti protein stvara nakupine amiloida u tkivu i organima u tijelu, uključujući i oko živaca, i ometa njihove normalne funkcije.
English: An overview of Onpattro and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Onpattro i zašto je odobren u EU-u
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Onpattro have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Onpattro nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: This reduces production of defective transthyretin, thereby reducing the formation of amyloids and relieving the symptoms of hATTR amyloidosis.
Croatian: To dovodi do smanjenog stvaranja oštećenog transtiretina, čime se smanjuje nastajanje amiloida i ublažavaju simptomi hATTR amiloidoze.
English: Other information about Onpattro
Croatian: Ostale informacije o lijeku Onpattro
English: To reduce the risk of infusion-related reactions, patients should be given corticosteroid medicines, paracetamol and medicines known as H1 and H2 blockers before receiving Onpattro.
Croatian: Radi smanjivanja rizika od reakcija povezanih s infuzijom, prije nego što prime lijek Onpattro bolesnicima se trebaju davati kortikosteroidni lijekovi, paracetamol i lijekovi poznati kao H1 i H2 blokatori.
English: The main measure of effectiveness was the change in the patients' nerve damage, as measured using a standard scale called ‘mNIS+7', with scores ranging from 0 to 304 (a higher score indicates more severe nerve damage).
Croatian: Glavna mjera učinkovitosti bila je promjena u oštećenju živaca bolesnika, izmjerena korištenjem standardne ljestvice pod nazivom „mNIS+7”, s rezultatima u rasponu od 0 do 304 (veći rezultat ukazuje na teže oštećenje živaca).
English: After 18 months of treatment, the mNIS+7 score decreased on average by 6 points with Onpattro (from around 81 to around 75 points), indicating a slight improvement of the patients' condition.
Croatian: Nakon 18 mjeseci liječenja rezultat mNIS+7 u prosjeku je smanjen za 6 bodova uz primjenu lijeka Onpattro (s oko 81 na oko 75 bodova), što upućuje na blago poboljšanje stanja bolesnika.
English: The European Medicines Agency therefore decided that Onpattro's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi lijeka Onpattro nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: Onpattro can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of patients with amyloidosis.
Croatian: Onpattro se izdaje samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju bolesnika s hATTR amiloidozom.
English: The company that markets Onpattro will provide educational materials for doctors and patients with information about how to give the medicine safely when at home and how to manage side effects.
Croatian: Tvrtka koja stavlja lijek Onpattro na tržište osigurat će edukacijski materijal za liječnike i bolesnike, koji će sadržavati informacije o sigurnoj primjeni lijeka kod kuće i upravljanju nuspojavama.
English: In patients with hATTR amyloidosis, a protein called transthyretin which circulates in the blood is defective and breaks easily.
Croatian: U bolesnika s hATTR amiloidozom protein naziva transtiretin koji cirkulira u krvi oštećen je i lako se raspada.
English: hATTR amyloidosis is rare, and Onpattro was designated an ‘orphan medicine' (a medicine used in rare diseases) on 15 April 2011.
Croatian: Budući da je hATTR amiloidoza rijetka bolest, lijek Onpattro dobio je status „lijeka za rijetku bolest” 15.travnja 2011.
English: In one main study involving 225 hATTR amyloidosis patients with stage 1 or 2 nerve damage, Onpattro was shown to be more effective than placebo (a dummy treatment) at slowing down the nerve damage caused by the disease.
Croatian: U jednom glavnom ispitivanju koje je obuhvatilo 225 bolesnika s hATTR amiloidozom koji su imali 1. stadij ili 2. stadij oštećenja živaca lijek Onpattro pokazao se djelotvornijim od placeba (prividno liječenje) u usporavanju oštećenja živaca koja ta bolest uzrokuje.
English: Onpattro is a medicine used to treat nerve damage caused by hereditary transthyretin (hATTR) amyloidosis, a disease in which abnormal proteins called amyloids build up in tissues around the body including around the nerves.
Croatian: Onpattro je lijek koji se primjenjuje za liječenje oštećenja živaca koja su uzrokovana nasljednom transtiretinskom amiloidozom (hATTR), bolešću pri kojoj se abnormalni proteini naziva amiloidi nakupljaju u tkivima tijela, uključujući i oko živaca.
English: The active substance in Onpattro, patisiran, is a ‘small interfering RNA' (siRNA), a very short piece of synthetic genetic material that has been designed to attach to and block the genetic material of the cell responsible for producing transthyretin.
Croatian: Djelatna tvar u lijeku Onpattro, patisiran, mala je interferirajuća ribonukleinska kiselina (siRNA), vrlo kratak sintetički genski materijal koji je namijenjen za vezivanje na genski materijal stanica koje stvaraju transtiretin i za njegovo blokiranje.
English: This compares with an increase on average by 28 points with placebo (from around 75 to around 101 points), indicating that nerve damage got worse in these patients.
Croatian: Za usporedbu, prilikom primjene placeba zabilježeno je prosječno povećanje od 28 bodova (s oko 75 na oko 101 bod), što upućuje na to da je u tih bolesnika došlo do pogoršanja oštećenja živaca.
English: What benefits of Onpattro have been shown in studies?
Croatian: Koje su koristi od lijeka Onpattro utvrđene u ispitivanjima?
English: Onpattro was shown to be effective at slowing down nerve damage in hATTR amyloidosis patients with stage 1 or stage 2 nerve damage; available data were not sufficient to assume a beneficial effect in stage 3 patients (those confined to a wheelchair).
Croatian: Lijek Onpattro pokazao se djelotvornim u usporavanju oštećenja živaca u bolesnika s hATTR amiloidozom koji imaju 1. stadij ili 2. stadij oštećenja živaca; dostupni podatci nisu bili dostatni da bi se pretpostavio povoljan učinak u bolesnika u 3. stadiju (koji su vezani za invalidska kolica).
English: How is Onpattro used?
Croatian: Kako se Onpattro koristi?
English: How does Onpattro work?
Croatian: Kako djeluje Onpattro?
English: Patients should also take vitamin A supplements during treatment with Onpattro.
Croatian: Bolesnici također trebaju uzimati nadomjeske vitamina
English: For the full list of side effects and restrictions with Onpattro, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja pri primjeni lijeka Onpattro potražite u uputi o lijeku.
English: Target species
Croatian: Ciljane vrste
English: Invented name
Croatian: Novoizu mljeno ime
English: PROTELOS with food and drink:
Croatian: PROTELOS s hranom i pićem:
English: What PROTELOS is and what it is used for
Croatian: Što je PROTELOS i za što se koristi
English: Your doctor will not prescribe PROTELOS for you if you are at particular risk.
Croatian: Vaš liječnik Vam neće propisati PROTELOS ako imate visoki rizik.
English: Your doctor will tell you how long you should continue to take PROTELOS.
Croatian: Liječnik će Vam reći kako dugo morate uzimati PROTELOS.
English: You can take PROTELOS again when you have finished taking these antibiotics.
Croatian: PROTELOS smijete ponovno početi uzimati nakon što ste prestali uzimati te antibiotike.
English: Other medicines and PROTELOS:
Croatian: Drugi lijekovi i PROTELOS:
English: If you take more PROTELOS than you should:
Croatian: Ako uzmete više PROTELOS-a nego što ste trebali:
English: What PROTELOS is and what it is used for What you need to know before you take PROTELOS How to take PROTELOS
Croatian: Što je PROTELOS i za što se koristi Što morate znati prije nego počnete uzimati PROTELOS
English: Children and adolescents PROTELOS is not intended for use in children and adolescents (below the age of 18).
Croatian: Djeca i adolescenti PROTELOS nije namijenjen za primjenu u djece i mladeži (mlađih od 18 godina).